
|Videos|August 18, 2022
Dr. Jang on current state of immunotherapy in advanced GU cancers
Author(s)Urology Times staff
There are still quite a few patients who still do not respond to immunotherapy, says Albert Jang, MD.
Advertisement
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses progress and unmet needs with immunotherapy for the treatment of patients with genitourinary cancers.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
2
FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5


















